Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Previously Treated Malignant Mesothelioma
NCT00509041Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Aug 2007
- Primary completion
- Feb 2010
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dasatinib in malignant mesothelioma, sponsored by Cancer and Leukemia Group B. Primary endpoint: 24 Week Progression Free Survival. Started Aug 2007; status: completed.
02
Drugs
dasatinib
03
Conditions
malignant mesothelioma
Beyond the preview
Go deeper on NCT00509041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00509041.